About Gero AI
Gero AI is a company based in Singapore (Singapore) founded in 2015. It operates as a AI-as-a-Service and Professional Services. Gero AI has raised $25.2 million across 4 funding rounds from investors including VitaDAO, Melnichek Investments and Leonid Lozner. Gero AI offers products and services including Anti-Aging Therapeutics and AI Drug Discovery Platform. Gero AI operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
- Headquarter Singapore, Singapore
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$23.7 K (USD)-2as on Dec 31, 2022
-
Net Profit
$2.91 K (USD)-41as on Dec 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$25.2 M (USD)
in 4 rounds
-
Latest Funding Round
$17 M (USD), Series A
Jun 17, 2026
-
Investors
VitaDAO
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gero AI
Gero AI offers a comprehensive portfolio of products and services, including Anti-Aging Therapeutics and AI Drug Discovery Platform.
Therapeutics are developed to extend healthy human lifespan.
Platform is used for discovering age-related disease treatments.
Funding Insights of Gero AI
Gero AI has successfully raised a total of $25.2M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $17 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gero AI
Gero AI has secured backing from 4 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include VitaDAO, Melnichek Investments and Leonid Lozner.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment services are provided to support innovative startups.
|
Locked | Locked | Locked | |
|
Bulba Ventures is focused on funding machine learning startups.
|
Locked | Locked | Locked | |
|
Online platform for collective funding and advancing longevity research
|
Locked | Locked | Locked |
Investor details for Gero AI
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gero AI
Investment portfolio details for Gero AI
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gero AI
Detailed financials for Gero AI
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gero Ai Comparisons
Peer comparison for Gero AI
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gero AI
Gero AI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, BigHat and Predictive Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An agentic AI platform is developed for biomedical research insights.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
Detailed competitors of Gero AI
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gero Ai
Complete news archive for Gero AI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gero AI
Gero AI was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Gero AI is headquartered in Singapore, Singapore.
Gero AI is a funded company, having raised a total of $25.2M across 4 funding rounds to date.
Annual revenue of Gero AI is $23.7K as on Dec 31, 2022.
Gero AI is engaged in creating therapeutics aimed at addressing the root causes of aging through physics and AI. The company operates at the intersection of theoretical physics, biology, and generative AI to develop drugs that restore resilience and delay age-related diseases. Their platform leverages over 100 million longitudinal medical records to map aging trajectories and identify causal pathways. Collaborations with pharmaceutical companies like Pfizer and Chugai are maintained to co-develop treatments for chronic age-related conditions. The mission is to double healthy human lifespan within a single generation by targeting systemic resilience loss.
Gero AI's top competitors include Owkin, Formation Bio and XtalPi.
Gero AI offers Anti-Aging Therapeutics and AI Drug Discovery Platform.
Gero AI has 4 investors. Key investors include VitaDAO, Melnichek Investments, Leonid Lozner, and Bulba Ventures.